ELIZABETH LARSON: Open Payments
NPI 1336800291 · SUGAR LAND, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,569 in 58 payments from 9 companies in 2025. Trend: 2023 $892 · 2024 $1,331 · 2025 $1,569
Food & beverage: $1,535Education: $34
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 17 | $604 |
| AstraZeneca Pharmaceuticals LP | 9 | $291 |
| Optinose US, Inc. | 11 | $173 |
| Novartis Pharmaceuticals Corporation | 6 | $168 |
| ARS Pharmaceuticals Operations, Inc. | 6 | $114 |
| Regeneron Healthcare Solutions, Inc. | 2 | $72 |
| GlaxoSmithKline, LLC. | 4 | $68 |
| Amgen Inc. | 2 | $53 |
| Organon LLC | 1 | $26 |
Products named: DUPIXENT, Xhance, TEZSPIRE, NEFFY, FASENRA, TRELEGY ELLIPTA, Rhapsido, NUCALA.
Industry payments across TX — which companies pay providers there.
